Fudan-LSE Lecture Series No.27
TITLE:
From Avoiding Disease to Designing Life: Ethics and the Future of Human Genome Editing
从避免疾病到设计生活：人类基因组编辑的伦理研究与未来探讨
SPEAKER/主讲人:
HOST/主持人:
TIME/时间:
VENUE/地点:
Jeffrey Kahn, PhD, MPH
Prof. Jing Yijia
15:30-17:20, Dec 9, 2019
Room 403, West Sub Building, Guanghua Towers
杰弗里·卡恩 教授
敬乂嘉 教授
2019年12月9日 15:30-17:20
光华楼西辅楼403室室
THE SPEAKER
Jeffrey Kahn is the Andreas C. Dracopoulos Director of the Johns Hopkins Berman Institute of Bioethics, and the Levi Professor of Bioethics and Public Policy. He is also Professor in the Department of Health Policy and Management in the Johns Hopkins University Bloomberg School of Public Health. He is an elected member of the National Academy of Medicine and Fellow of the Hastings Center.
ABSTRACT
The lecture will focus on the relationship between PRC and the European Union, with a sThe ethical and policy challenges of genome editing are very much in the public awareness due to the rapid advances in the development and uses of the technologies, but the issues and challenges have been part of the bioethics and health policy debates for at least two decades. This presentation will chart that history and the issues that were relevant 20 years ago as well as today through the discussion of three short cases of the combined uses of genetic and reproductive technologies.
Ethics, Regulation and Beyond: Policy Aspects of Research with Pregnant Women
伦理，法规及其他：有关孕妇政策的研究
Anna Mastroianni, JD, MPH 安娜·马斯特罗安妮 教授
Anna Mastroianni is Professor of Law at the University of Washington (UW) School of Law and Associate Director of UW’s Institute for Public Health Genetics. She serves on national and international consensus, advisory, and oversight committees, including those at the U.S. National Academies of Sciences, Engineering and Medicine and National Institutes of Health.
The near-routine exclusion of pregnant women from clinical research has resulted in a dearth of data to inform medical decisions about safe and effective treatments and preventives for this complex population. This presentation will describe the problem and its origins and examine aspects of the policy landscape—including recent international ethics guidance, regional and national regulatory approaches, and practices—that frame responses to this challenging issue. This examination will reveal that regulatory approaches in some cases can be more restrictive than international ethics guidance, and that even when policies expressly permit research with pregnant women, practical challenges arising throughout the research pathway continue to stymie advancement in addressing research needs of this population.
ORGANIZERS
Institute for Global Public Policy (IGPP)
LSE-Fudan Research Centre for Global Public Policy
Center for Biomedical Ethics, Fudan University
